Citizens Initiates Coverage on Opus Genetics with Outperform Rating
On April 28, Citizens initiated coverage of Opus Genetics (NASDAQ:IRD) with an 'Outperform' rating and a $12 price target. The firm highlighted the company's focus on AAV-based gene therapies for inherited retinal diseases as offering significant commercial potential.
Topics: biopharmaceutical financing agreement gene therapy stock coverage